Scan for early esophagus cancer using infused antibody dyes
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study uses special drug dyes (bevacizumab and cetuximab, each tagged for imaging) during an esophagus scope to help doctors find very early abnormal cells, like low- or high-grade pre-cancer and superficial cancer. If you qualify, the goal is earlier detection and better targeting during diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) and can give written consent
- You have Barrett’s esophagus without dysplasia, or with suspected/diagnosed low-grade or high-grade dysplasia, or very superficial esophageal adenocarcinoma
- You are already planning an esophagus endoscopy for diagnosis and/or treatment
- You have not had prior radiation therapy for esophageal cancer
- You have not had prior bevacizumab or cetuximab (and you do not have an allergy to these)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two simple, non-surgical methods to look for Barrett's esophagus (a change in the lining of the swallowing tube) and early esophageal cancer. It is for people who are at higher risk or lower risk, but have never had Barrett's or cancer before.
This study tests a new, less invasive way to detect precancerous changes or early cancer in Barrett's esophagus. It uses a sponge or brush to collect cells from your esophagus during a routine endoscopy, which may help find problems earlier and avoid more invasive procedures.
This study tests minimally invasive, sample-based tests during an endoscopy to find Barrett’s esophagus and help sort it from esophageal cancer risk. It may help doctors spot changes earlier and more accurately using less invasive methods than standard tissue testing alone.
This trial tests a new way to see cancer during a bronchoscopy. A special dye (bevacizumab with a fluorescent marker) is used to make tumors glow under a special light, which may help doctors find and remove cancer more precisely.
This study tests a new glowing dye that highlights dangerous cell changes in the esophagus during a routine camera procedure. It may help doctors spot and treat Barrett's esophagus and early cancers earlier and more accurately.
This trial tests whether special fluorescent dyes attached to immune drugs can help doctors see esophageal cancer more clearly during an endoscopy. It may help guide treatment decisions.
Hear when a new Barrett's Esophagus Without Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.